Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.

Bradley JS, Armstrong J, Arrieta A, Bishai R, Das S, Delair S, Edeki T, Holmes WC, Li J, Moffett KS, Mukundan D, Perez N, Romero JR, Speicher D, Sullivan JE, Zhou D.

Antimicrob Agents Chemother. 2016 Aug 8. pii: AAC.00862-16. [Epub ahead of print]

PMID:
27503642
2.

Congenital Herpes Simplex Virus in the Newborn: A Diagnostic Dilemma.

Purewal R, Costello L, Garlapati S, Mitra S, Mitchell M, Moffett KS.

J Pediatric Infect Dis Soc. 2016 Sep;5(3):e21-3. doi: 10.1093/jpids/piw013. Epub 2016 Mar 28.

PMID:
27021037
3.

Bilateral maculopathy in a patient with ataxia telangiectasia.

Gioia LV, Bonsall D, Moffett K, Leys M.

J AAPOS. 2016 Feb;20(1):85-8. doi: 10.1016/j.jaapos.2015.10.005.

PMID:
26917084
4.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2016 Feb;169:116-21.e2. doi: 10.1016/j.jpeds.2015.08.042. Epub 2015 Sep 19.

PMID:
26388208
5.

Word-finding impairment in veterans of the 1991 Persian Gulf War.

Moffett K, Crosson B, Spence JS, Case K, Levy I, Gopinath K, Shah P, Goyal A, Fang Y, Briggs RW, Hart J Jr, Moore A, Haley RW.

Brain Cogn. 2015 Aug;98:65-73. doi: 10.1016/j.bandc.2015.05.005. Epub 2015 Jun 23.

PMID:
26114921
6.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

7.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group.

Lancet Respir Med. 2014 Nov;2(11):902-10. doi: 10.1016/S2213-2600(14)70218-8. Epub 2014 Oct 9.

PMID:
25311995
8.

Management of prediabetes through lifestyle modification in overweight and obese African-American women: the Fitness, Relaxation, and Eating to Stay Healthy (FRESH) randomized controlled trial.

Bernstein AM, Gendy G, Rudd N, Doyle J, Fay S, Moffett K, Morrison S, Bena J, Cotey S, Roizen MF, Golubic M.

Public Health. 2014 Jul;128(7):674-7. doi: 10.1016/j.puhe.2014.04.005. Epub 2014 Jul 2. No abstract available.

PMID:
24996961
9.

Hydrological controls on methylmercury distribution and flux in a tidal marsh.

Zhang H, Moffett KB, Windham-Myers L, Gorelick SM.

Environ Sci Technol. 2014 Jun 17;48(12):6795-804. doi: 10.1021/es500781g. Epub 2014 May 28.

PMID:
24828335
10.

Beliefs about preventive care, individual health, and lifestyle change among low-income African American women at risk for diabetes.

Bernstein AM, Rudd N, Gendy G, Moffett K, Adams J, Steele S, Frietchen M.

Holist Nurs Pract. 2014 Jan-Feb;28(1):24-30. doi: 10.1097/HNP.0000000000000006.

PMID:
24304627
11.

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.

12.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

13.

Pediatric infectious disease: unusual head and neck infections.

Moffett KS.

Oral Maxillofac Surg Clin North Am. 2012 Aug;24(3):469-86. doi: 10.1016/j.coms.2012.05.008. Epub 2012 Jun 26. Review.

PMID:
22739434
14.

Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.

Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Macrolide Study Team.

Pediatr Pulmonol. 2012 Jul;47(7):641-8. doi: 10.1002/ppul.21601. Epub 2012 Jan 3.

PMID:
22684984
15.

Long term effects of denufosol tetrasodium in patients with cystic fibrosis.

Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group.

J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8.

16.

Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis.

Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H; Liprotamase 767 Study Group.

J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):248-57. doi: 10.1097/MPG.0b013e31823315d1.

PMID:
22266487
17.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group.

N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.

18.

Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).

Moffett K, Konteatis Z, Nguyen D, Shetty R, Ludington J, Fujimoto T, Lee KJ, Chai X, Namboodiri H, Karpusas M, Dorsey B, Guarnieri F, Bukhtiyarova M, Springman E, Michelotti E.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7155-65. doi: 10.1016/j.bmcl.2011.09.078. Epub 2011 Sep 28.

PMID:
22014550
19.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients.

Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M; Liprotamase 726 Study Group.

J Cyst Fibros. 2011 Dec;10(6):443-52. doi: 10.1016/j.jcf.2011.07.001. Epub 2011 Aug 9.

20.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk